These guidelines contain the requirements for certification of a Physical Containment Level 3 (PC3) Facility issued pursuant to section 90 of the Gene Technology Act 2000 (the ACT) and state legislation.
Commercial supply of a genetically modified COVID-19 vaccine
This guidance accompanies the Guidelines for certification of a Physical Containment Level 3 (PC3) Facility effective 1 December 2022.
Checklist for annual inspection against the usual Conditions of Certification as detailed in the Gene Technology Regulator’s Guidelines for Certification of a Physical Containment Level 3 Facility.
Checklist for the inspection of a new facility against the usual Conditions of Certification as detailed in the Gene Technology Regulator’s Guidelines for Certification of a Physical Containment Level 3 Facility Version 1.0 - 1 December 2022
Our staff contribute to a range of academic works in peer-reviewed journals and book sections. Here are the various publications, and the OGTR staff who were involved.
Trial of a genetically modified vaccine against devil facial tumour disease in Tasmanian devils
This Communique covers matters considered at the 17th meeting of the Gene Technology Ethics and Community Consultative Committee (22 November 2022).
This Communiqué covers matters considered at the 58th meeting of the Gene Technology Technical Advisory Committee (29 November 2022).
Details of OGTR monitoring and compliance activities during the quarter ended 31 December 2022.